Santhera receives FDA Fast Track Designation for Raxone/Catena for the treatment of Duchenne Muscular Dystrophy
9 April 2015 | By Victoria White
Santhera has announced that the FDA has granted Fast Track designation for Santhera's Raxone/Catena for the treatment of Duchenne Muscular Dystrophy...